Moreover, in oxaliplatin-resistant colon cancer cells, DKK1 signaling is remarkably increased that contributes to AKT activation, and suppression of DKK1 signaling significantly promotes the sensitivity to oxaliplatin, suggesting that DKK1 functions as a chemoresistant factor in colon cancer through enhancing AKT activation [28]. Here, DKK1 is linked to malignant colon neoplasm.